This whole fiasco should be a learning lesson for all bigshot CEOs who think they can turn their development stage biotech which has been losing hundreds of millions a year, into a pharmaceutical cash cow.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.